With a suite of products spanning a broad range of therapeutic areas,
Forest is delivering on our mission to improve patients' lives.
R&D at Forest is focused on identifying strong, medically relevant product candidates
and guiding them through the complex development lifecycle, from proof-of-concept
NEW YORK—(BUSINESS WIRE)—Forest Laboratories, Inc. (NYSE: FRX) today announced a series of
significant strategic actions to streamline operations and reduce costs, leverage the Company’s balance sheet
by issuing new debt, and return cash to shareholders through a new share repurchase authorization and an
accelerated share repurchase program.
NEW YORK—(BUSINESS WIRE)—Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its
executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden
the organization as part of Project Rejuvenate.
With a unique partnership-focused business model and a strong track record
of commercial achievement, Forest has built a pharmaceutical business for
today's environment. The Company is fulfilling its objective of making a
meaningful difference in patients' lives through an expanded and diversified
product portfolio and the most robust pipeline in our history.
Forest employees are driven by a shared passion to help improve patients' lives
through medicine. Forest offers a variety of opportunities for experienced professionals,
sales professionals, graduate students, and others to build their careers in a
about joining our team.
Thank you for visiting www.FRX.com.
You are now being redirected to an external site.